Roche Softens TIGIT Blow With Poseida Buyout
The SKYSCRAPER-01 trial’s failure to generate an overall survival benefit is the biggest blow yet to the TIGIT inhibitor class, but Roche looking to move on with its buyout of the CAR-T therapy company.
The SKYSCRAPER-01 trial’s failure to generate an overall survival benefit is the biggest blow yet to the TIGIT inhibitor class, but Roche looking to move on with its buyout of the CAR-T therapy company.